Mentioned 8× · first seen 28-apr-2026 · last seen 13-sep-2026

Navitoclax + Venetoclax + Decitabine combination

Current understanding

To be populated as evidence accumulates.

Evidence log

2026-08-01 — Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.: Phase I dose-escalation study (trial-early) reports the triplet is safe and tolerable in advanced myeloid neoplasms including AP/BP-MF and MDS/MPN overlap, with a 60% objective response rate and an established recommended phase II dose. (novelty: 3)
2026-07-01 — Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms: Cross-reference: a parallel phase I trial (trial-early) is testing pacritinib + venetoclax + azacitidine as an alternative HMA + BCL-2 inhibitor triplet in AP/BP-MPN, substituting JAK2/IRAK1 inhibition (pacritinib) for BCL-XL inhibition (navitoclax) as the third-agent addition. (novelty: 4)
2026-06-05 — A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts: Cross-reference: a phase II trial in higher-risk CMML/MDS with excess blasts is evaluating cladribine + low-dose cytarabine + venetoclax alternating with azacitidine + venetoclax — another approach to intensifying the HMA + venetoclax backbone in advanced myeloid neoplasms, here by adding nucleoside analog chemotherapy rather than BCL-XL inhibition. (novelty: 3)
2026-05-20 — Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN: Cross-reference: a parallel phase I/II trial is testing venetoclax added to FluBu conditioning plus venetoclax + HMA (azacitidine or oral decitabine/cedazuridine) as post-transplant maintenance in AML/MDS/CMML/MDS-MPN-U, illustrating an alternative peri-transplant deployment of the HMA + BCL-2 inhibitor backbone rather than the BCL-2/BCL-XL triplet. (novelty: 3)
2026-05-13 — Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm: Related regimen: a phase II trial (trial-early) is evaluating ASTX727 + venetoclax (oral HMA + BCL-2 inhibitor doublet) in CMML/MDS-MPN, a simpler all-oral analogue to the navitoclax + venetoclax + decitabine triplet in advanced myeloid neoplasms. (novelty: 3)
2026-04-23 — A Study of BGB-11417 in Participants With Myeloid Malignancies: cross-connection with bgb-11417-bcl2-inhibitor-myeloid: Both leverage BCL-2 family inhibition combined with hypomethylating agents in myeloid malignancies; BGB-11417 represents a next-generation BCL-2 inhibitor in the same therapeutic class as venetoclax. (novelty: 3)
2026-03-05 — Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR): cross-connection with azacitidine-venetoclax-cmml: Both apply venetoclax-based regimens to advanced myeloid neoplasms with HMA backbones; AVENHIR uses the simpler doublet in CMML while the navitoclax triplet adds BCL-XL inhibition in myelofibrosis/AML overlap. (novelty: 3)
2026-04-16 — Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm: Cross-reference: a parallel triplet strategy (azacitidine + venetoclax + gilteritinib) is being tested in phase I/II for FLT3-mutated R/R AML, CMML, and high-risk MDS/MPN, illustrating a broader trend of layering a third targeted agent (BCL-XL or FLT3 inhibition) onto the HMA + venetoclax backbone in advanced myeloid neoplasms. (novelty: 3)
2026-03-23 — Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis: cross-connection with navitoclax-ruxolitinib-combination: Both regimens employ navitoclax-driven BCL-2/BCL-XL inhibition in myeloid neoplasms; the doublet (with ruxolitinib) targets MF in a Phase 3 setting, while the triplet (with venetoclax + decitabine) targets advanced myeloid neoplasms in Phase I. (novelty: 3)
2026-01-28 — Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms: Phase I trial (trial-early) evaluating safety of navitoclax + venetoclax + decitabine triple combination in advanced myeloid neoplasms including myelofibrosis — first-in-combination dual BCL-2/BCL-XL inhibition layered on hypomethylating backbone. (novelty: 3)